These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28189366)

  • 21. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
    Ungerleider JT; Andyrsiak T; Fairbanks L; Ellison GW; Myers LW
    Adv Alcohol Subst Abuse; 1987; 7(1):39-50. PubMed ID: 2831701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.
    de Vries M; Van Rijckevorsel DC; Vissers KC; Wilder-Smith OH; Van Goor H
    Br J Clin Pharmacol; 2016 Mar; 81(3):525-37. PubMed ID: 26505163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial.
    Turcotte D; Doupe M; Torabi M; Gomori A; Ethans K; Esfahani F; Galloway K; Namaka M
    Pain Med; 2015 Jan; 16(1):149-59. PubMed ID: 25288189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect profile of paracetamol, Δ9-THC and promethazine using an evoked pain test battery in healthy subjects.
    van Amerongen G; Siebenga P; de Kam ML; Hay JL; Groeneveld GJ
    Eur J Pain; 2018 Aug; 22(7):1331-1342. PubMed ID: 29635857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.
    Fairhurst C; Kumar R; Checketts D; Tayo B; Turner S
    Dev Med Child Neurol; 2020 Sep; 62(9):1031-1039. PubMed ID: 32342496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].
    Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M
    Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
    Corey-Bloom J; Wolfson T; Gamst A; Jin S; Marcotte TD; Bentley H; Gouaux B
    CMAJ; 2012 Jul; 184(10):1143-50. PubMed ID: 22586334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
    Wade DT; Makela P; Robson P; House H; Bateman C
    Mult Scler; 2004 Aug; 10(4):434-41. PubMed ID: 15327042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury.
    Hagenbach U; Luz S; Ghafoor N; Berger JM; Grotenhermen F; Brenneisen R; Mäder M
    Spinal Cord; 2007 Aug; 45(8):551-62. PubMed ID: 17043680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
    Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
    Giacoppo S; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2017 Oct; 17():22-31. PubMed ID: 29055461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.
    Ware MA; Wang T; Shapiro S; Robinson A; Ducruet T; Huynh T; Gamsa A; Bennett GJ; Collet JP
    CMAJ; 2010 Oct; 182(14):E694-701. PubMed ID: 20805210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Russo EB
    Neurology; 2003 Feb; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
    [No Abstract]   [Full Text] [Related]  

  • 36. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study.
    de Vries M; van Rijckevorsel DCM; Vissers KCP; Wilder-Smith OHG; van Goor H;
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1079-1086.e4. PubMed ID: 27720917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP
    Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
    Conte A; Bettolo CM; Onesti E; Frasca V; Iacovelli E; Gilio F; Giacomelli E; Gabriele M; Aragona M; Tomassini V; Pantano P; Pozzilli C; Inghilleri M
    Eur J Pain; 2009 May; 13(5):472-7. PubMed ID: 18603457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients.
    Schimrigk S; Marziniak M; Neubauer C; Kugler EM; Werner G; Abramov-Sommariva D
    Eur Neurol; 2017; 78(5-6):320-329. PubMed ID: 29073592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.